Urine Drug Testing Methadone 101 Methadone for hospitalists



Similar documents
Interagency Guideline on Opioid Dosing for Chronic Non-cancer Pain (CNCP)

Appropriate Use of UDT to Improve Patient Care

This is the written version of our Hot Topic video presentation available at: MayoMedicalLaboratories.com/hot-topics

Drug Testing to Support Pain Management

Central Government Laboratory Department of Health and Environment

Triage, Assessment & Treatment Methadone 101/Hospitalist Workshop

Rationale for Urine Drug Testing (UDT)

Drug Utilization Is On The Rise

Medical Malpractice Treatment Alprazolam benzodiazepine - A Case Study

Southlake Psychiatry. Suboxone Contract

Triage, Assessment & Treatment

URINE DRUG TESTING. Effective December 1 st, 2012

PtProtect Pain Medication Management Program Monitors Patient Compliance

PAYMENT POLICY STATEMENT

Appropriate utilization of drug tests for pain management patients

Hillsborough Community College - Ybor City Campus 1025C Laboratory Exercise 9: Testing Urine for the Presence of Drugs Introduction

DUI in Southern Ohio MATT 2006

Discontinuation: Involuntary Discharge

Table of Contents. I. Introduction II. Summary A. Total Drug Intoxication Deaths B. Opioid-Related Deaths... 9

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

A Review of the Impacts of Opiate Use in Ontario: Summary Report

Care Management Council submission date: August Contact Information

Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain

Toxicology CPT Code Changes for 2016

URINE DRUG TESTS IN A PRIVATE CHRONIC PAIN PRACTICE

DRUG AND ALCOHOL DETOXIFICATION: A GUIDE TO OUR SERVICES

Drug- and Alcohol-Related Intoxication Deaths in Maryland, 2014

2015 OPSC Annual Convention. syllabus. February 4-8, 2015 Hyatt Regency Mission Bay San Diego, California

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Urine Drug Testing In Pain Management and Opioid Abuse Treatment Corporate Medical Policy

3.1. The procedure shall be applicable to all University employees.

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist

COMMUNITY BUPRENORPHINE PRESCRIBING IN OPIATE DEPENDENCE

LC-MS for Pain Management Support. Gwen McMillin, PhD, DABCC(CC,TC) University of Utah ARUP Laboratories

OVERVIEW WHAT IS POLyDRUG USE? Different examples of polydrug use

LC-MS for Pain Management Support

Opioid overdose can occur when a patient misunderstands the directions

Collection Instructions for ARUP Drug Screen Kit #49204

MOSAIC DES MOINES Alcohol/Drug Free Workplace Policy

SCOTTISH PRISON SERVICE DRUG MISUSE AND DEPENDENCE OPERATIONAL GUIDANCE

New York State Office of Alcoholism & Substance Abuse Services Addiction Services for Prevention, Treatment, Recovery

Methadone and Pregnancy

METHADONE SUBSTITUTION THERAPY PROGRAM AND TOXICOLOGICAL STUDIES

Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence

Drug Testing for Criminal Justice Involved Individuals in Michigan

8/1/2014. Who We Are. BHG s Medical Mission. BHG Company Overview

Support to Primary Care from Derbyshire Substance Misuse Service for prescribed / OTC drug dependence

SERVING GRANITE CITY, MITCHELL, AND PONTOON BEACH

MAT Disclosures & Consents 1 of 6. Authorization & Disclosure

NALCOR ENERGY ALCOHOL AND DRUG PROGRAM REQUIREMENTS FOR CONTRACTORS

What Does the Drug Test Tell Us

How To Treat A Drug Addiction

2013 Annual Toxicology Report

2015 REPORT Steven W. Schierholt, Esq. Executive Director

Increasing Access to Opioid Addiction Treatment

5317 Cherry Lawn Rd, Huntington, WV Phone: (304) Fax: (304) Welcome

HEAT AND FROST INSULATORS AND ALLIED WORKERS LOCAL 45 JOINT APPRENTICESHIP AND TRAINING COMMITTEE DRUG-FREE SUBSTANCE ABUSE POLICY AND PROCEDURE

INSTRUCTIONS AND PROTOCOLS FOR THE IMPLEMENTATION OF MEDICATION-ASSISTED TREATMENT FOR OPIOID/OPIATE DEPENDENCE

Clinical Drug Testing in Primary Care

The Role of Urine Drug Testing In Chronic Pain Management: 2013 Update

Urine Drug Testing in Clinical Practice

Substitution Therapy for Opioid Dependence The Role of Suboxone. Mandy Manak, MD, ABAM, CCSAM Methadone 101-Hospitalist Workshop, October 3, 2015

Magee-Womens Hospital

Naltrexone Pellet Treatment for Opiate, Heroin, and Alcohol Addiction. Frequently Asked Questions

Review of Drug Use and Service Responses in North West Tasmania. Final Report

ORDER OF EMERGENCY SUSPENSION OF LICENSE

DRUG SCREENING POLICY AND PROCEDURES Effective August 31, 2015

What Parents Need to Know

Opiates Agreements and Drug testing in Pain Management

Indiana State Department of Toxicology 2012 Annual Report

Drug Abuse & Alcoholism

Medicaid Behavioral Health Clinic Rehabilitation Services Manual

Section: Laboratory Last Reviewed Date: December Policy No: 68 Effective Date: April 1, 2016

In 2010, approximately 8 million Americans 18 years and older were dependent on alcohol.

Jane Maxwell, UT Addiction Research Institute, Prescription Pain Medications and Heroin: A Changing Picture

Neurobiology and Treatment of Opioid Dependence. Nebraska MAT Training September 29, 2011

BEST PRACTICES IN DRUG TESTING OF HEALTHCARE PROFESSIONALS

2.2 Keeping Patients Safe: A Case Study on Using Prescription Monitoring Program Data in an Outpatient Addictions Treatment Setting

RULES OF THE TENNESSEE DEPARTMENT OF MENTAL HEALTH AND DEVELOPMENTAL DISABILITIES

FREQUENTLY ASKED QUESTIONS Oral Fluid Drug Testing with Oral-Eze

Simultaneous Quantitation of 43 Drugs in Human Urine with a Dilute-and-Shoot LC-MS/MS Method

ARCHIVED BULLETIN. Product No L SEPTEMBER 2004 U. S. D E P A R T M E N T O F J U S T I C E

Treatment of Opioid Dependence: A Randomized Controlled Trial. Karen L. Sees, DO, Kevin L. Delucchi, PhD, Carmen Masson, PhD, Amy

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

How To Treat Anorexic Addiction With Medication Assisted Treatment

Asset Marketing Services, Inc. Drug and Alcohol Testing Policy (MN)

Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances

Testimony Engrossed House Bill 1101 Department of Human Services Senate Human Services Committee Senator Judy Lee, Chairman February 19, 2013

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

Methadone for Substance Abuse. By: Angela M. Martinez

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas

Drug Abuse Trends in Miami-Dade and Broward Counties, South Florida: June 2013 James N. Hall 1

Opioid Contracts: A Tool for Providing Relief and Preventing Abuse?

Transcription:

Urine Drug Testing Methadone 101 Methadone for hospitalists Dr. Patricia Mark MB, BCh

LEARNING OBJECTIVES Clarify the purpose of urine drug testing Distinguish between UDT for detection of illicit drug use and monitoring adherence to treatment plan Describe practicalities of UDT Understand the interpretation of UDT results Understand limitation of UDT

Basics Urine drug testing must always be discussed with patients ahead of time. It is part of the physician/ patient agreement which all patients on MMP sign. All patients must be treated the same way, and always with respect. UDT is not a means of punishing rather, it is a tool to help best management.

BACKGROUND FOR UDT Urine is the best biologic specimen for detecting certain drugs. Longer window of detection for most drugs. No standard test for all drugs, so screening may be a misnomer, hence the title Urine Drug Testing. Must be used in context of detailed history of all medications. Must be undertaken in a respectful way and honest way.

Why? To ensure that prescribers can help and support MMP patients to begin recovery and achieve stability. Provides objective evidence of compliance with the treatment plan Are patients taking medications as prescribed? Are patients using illicit substances? Adjust treatment plans if necessary to work towards best outcomes for patients on opioids for opioid addiction or chronic pain.

Why? UDT is only one of several ways in which physicians can assess patients stability. Careful history taking Frequent reassessment Contact with pharmacist Collateral information

Value of self-reporting of noncompliance Can be significantly unreliable in patients suffering from addiction disorders. If UDT is found to be discordant with history of medications: Review medical records Review PharmaNet Collateral information from significant others

How? Enzyme Immunoassay (EIA) Specific anti-drug antibody added to urine. If that drug is present, antibody binds to drug giving a measurable indicator reaction as positive. MMP protocol tests for: methadone metabolite opiates cocaine benzodiazepine methamphetamine oxycodone

How? Gas chromatography Mass spectroscopy GC separates and quantifies drug components. MS specifically identifies them. Gold standard of urine toxicology but expensive Each test is about $40 Should be used for clarification where there is a question about drug identification on EIA

UDT - How? Supervised: Patients remove bulky clothing, leave bags with staff, specimen is temperature tested before being sent to lab for appropriately ordered test or for POC testing. Witnessed: Patient witnessed while producing specimen. Less commonly used as can be seen to be intrusive and demeaning. May at times be necessary.

WASHROOMS & STANDARDS FOR UDT COLLECTION Should be on the methadone clinic or FP office premises. Hot water should be turned off. Lab tech or staff member should have immediate access to UDT specimen for temperature strip check. If unusually pale, this should be noted or specific gravity checked. If specimen does not meet temperature requirements, the patient should be requested to produce another specimen. No prescription until UDT done.

When? May be collected at every clinic visit may not necessarily be tested. Random samples collected at varying intervals every 3 or 4 months and tested. Random UDT is preferable and more valuable and should be used for all patients with methadone carries.

Which opiates show up in UDT? Metabolites of: Heroin Morphine Codeine shows as morphine which is a metabolite of codeine Reliably detected on regular EIA testing

UDT LIMITATIONS Cocaine is highly specific as the antibody reacts only to cocaine and its principle metabolite. Amphetamine/methamphetamine highly cross reactive and detects other sympathomimetic amines e.g. ephedrine & pseudoephedrine. Opiate testing does not distinguish between morphine, heroin and codeine. Does not always detect semi-synthetics e.g. hydromorphone. Oxycodone needs its own specific antibody. Methadone & buprenorphine also need specific antibody.

Drugs of interest to methadone prescribers: oxycodone Is a semi-synthetic opioid, shows up in only about 10% positive tests. There is a specific EIA for oxycodone that is reliable & is included in POC test kits. Problems associated with oxycodone screening include false negatives for patients for whom oxycodone has been prescribed.

Other synthetic opioids: fentanyl Wholly synthetic and does not react with EIA morphine antibody. Needs either a specific EIA or GCMS to confirm presence or absence. Patients who are on fentanyl and show positive for opiates WHICH IS NOT POSSIBLE using standard tests are abusing other opioids which react with the standard EIA testing.

Methadone Is a wholly synthetic opioid which does not show up on standard testing. Needs a specific EIA for methadone metabolites which is virtually 100% sensitive. All UDS kits, whether point-of-care testing or in labs, use the specific EIA for methadone metabolites to eliminate possibility of adulteration with methadone.

Hydromorphone Is a semi-synthetic opioid which may or may not show up on routine UDS with standard opioid EIA testing but more likely to show up if very high dosing Will require GCMS or specific EIA to confirm presence or absence

Buprenorphine Is a semi-synthetic morphine-based molecule which has been so altered that does not show up on standard opioid EIA testing Specific and highly reliable EIA tests available in labs and in point-of-care test kits Is now becoming more widely prescribed and there is a specific simple dip stick test which can be used

Benzodiazepines Always monitored by UDT, as are contraindicated for patients on the MMP. EIA for benzos is based on the diazepam antibody. Shows reliably positive test for diazepam and alprazolam. Most diazepam EIAs do not detect clonazepam or lorazepam. GCMS may be needed to identify both these benzos.

POC TESTING POC testing now commercially available, simple to perform and gives rapid information while patient is in the office Several companies are involved in production Is covered by MSP Uses immunoassay methods with all the advantages and disadvantages

POC TESTING MMP Protocol POC also tests for: Methadone metabolites Opiates Cocaine Benzodiazepines Amphetamine Oxycodone

Urine detection time frame Methadone 4 5 days Opiates 2 3 days Cocaine/metabolites 2 4 days Benzodiazepines 1 42 days THC single use 2 3 days THC habitual use up to 12 weeks Methamphetamine 3 5 days Alcohol 6 24 hours

UDT interpretation What shows in UDT is important. What does NOT show in UDT is equally important: Methadone metabolites if methadone prescribed Benzos especially clonazepam Synthetic and semi-synthetic opioids Beware of very dilute urine, may be an attempt to dilute out drug metabolites. PharmaNet essential to confirm what patients should be taking if prescribed. Results should always be reviewed with the patient.

Limitations of UDT Assesses the presence or absence of a particular drug and/or metabolite at a specific threshold of concentration at a specific time. Unexpected result does not diagnose Abuse or addiction Physical dependence Diversion. Does not provide accurate information on Time of last use Amount and frequency of use.

Potential harms of UDT Incorrect interpretation of UDT could result in: Unwarranted discontinuation of opioids Damage to physician/patient relationship If very unexpected result, especially with POC testing, always get laboratory confirmation Potential for false reassurance Adulteration/cheating Alteration of behaviour in anticipation of UDT, hence need for random UDS

Consequences of positive urine drug tests Always review results of UDT with patient UDT result is one of many factors taken into account when making clinical decisions Review physician/patient agreement Review treatment plan Increase frequency of office visits Methadone dose if opiate positive: is it appropriate? May have to discontinue carries in the face of instability Increase counselling and other support services

ADDICTION BASICS FOR HOSPTIALISTS When opiate dependent patients admitted: If possible, collateral information from family, friends or family physician If necessary, talk to the pharmacist PharmaNet Previous medical records Urine drug testing on admission and serially as necessary thereafter Appropriate blood work on admission

METHADONE ESSENTIALS FOR HOSPITALISTS Drug addicted patients needing medical care are frequently admitted under hospitalists Can be challenging and disruptive Self-reporting usually not reliable UDT is objective evidence which will help to make treatment planning more effective

UDT IN HOSPITAL Most hospital labs look for a number of other drugs as they are geared more for drug overdose investigations. Some labs do not look for methadone metabolites. MRPs can request the MMP protocol which some hospitals will do.

Polydrug use Most patients with addictions disorders are polydrug users. Very few stick to one drug of choice. Important to consider all possibilities when ordering UDT. UDT may be very informative about prescribed medication not being taken. Collateral history and PharmaNet very helpful as many abused drugs are now prescription drugs.

INTERPRETATION OF UDT UDT results should always be reviewed with the patient If the patient is on opiates as confirmed by PharmaNet and UDT, will have to be supported in hospital to prevent withdrawal Opiate withdrawal is unpleasant but unlike alcohol withdrawal is not dangerous Patients in hospital are likely to leave AMA if not supported to prevent withdrawal Opiate dependent patients may be suitable candidates for the MMP and may be initiated while in hospital

Treatment planning While in hospital should include: addictions consult if possible mental health assessment as many addicted patients suffer from concurrent mental ill health discussion about opioid substitution for opiate dependant patients: omethadone osuboxone Patients initiated on to methadone or suboxone must have community prescriber available to continue prescribing after discharge

Conclusion Urine drug testing is an important part of the comprehensive care of patients who are on MMP or are receiving opioids for chronic pain and must be undertaken in a respectful, nonjudgmental manner. Should be considered as an objective test within the greater biopsychosocial context. Should always be interpreted in the context of broad based clinical care of the individual patient.

And remember This is a difficult patient population Most of them have had terrible lives They are accustomed to being treated without respect Requesting UDT can seem like an insult although on the street all opiate dependent patients know that UDT is part of treatment The way we treat our addicted patients may make a huge difference in their lives We have the power to make that difference

UDT for methadone prescribers Thank you